Clinical Trial Update: Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303） [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for Anlotinib in advanced non-small cell lung cancer (ALTER0303) reporting completed Phase 2 and Phase 3 studies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 2, Phase 3 | Status: COMPLETED